Usefulness of various antibiotics against Mycobacterium avium-intracellulare, measured by their mutant prevention concentration

被引：9

作者：

Rodríguez, JC ^{[1
]}

Cebrián, L ^{[1
]}

López, M ^{[1
]}

Ruiz, M ^{[1
]}

Royo, G ^{[1
]}

机构：

[1] Univ Miguel Hernandez, Hosp Gen Univ Elche, Secc Microbiol, Alicante 03203, Spain

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2005年 / 25卷 / 03期

关键词：

mutant prevention concentration; fluoroquinolones; linezolid; macrolides; Mycobacterium avium-intracellulare;

D O I：

10.1016/j.ijantimicag.2004.09.018

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

This study looked the selection of resistant mutants in Mycobacterium avium-intracellulare during antibiotic treatment. The mutant prevention concentration (MPC) of 20 Mycobacterium avium and 12 Mycobacterium intracellulare isolates was determined. Fifty percent of Mycobacterium avium strains had MPC (MPC50) values lower than 16, 64, 40, 55 and 60 mg/L for rifabutin, rifampicin, ciprofloxacin, levofloxacin and moxifloxacin, respectively. In the case of Mycobacterium intracellulare, 50% had MPC (MPC50) values below 60, 30, 35, 16, 2.5 and 14 mg/L for linezolid, rifabutin, levofloxacin, gatifloxacin, moxifloxacin and clarithromycin, respectively. The high capacity for selecting resistant mutants of all the antibiotics studied emphasises the need to restore the immune system if necessary and to administer combined treatments in order to cure patients. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

页码：221 / 225

页数：5

共 36 条

[11] Mutant prevention concentration as a measure of antibiotic potency:: Studies with clinical isolates of Mycobacterium tuberculosis [J].

Dong, YZ ;

Zhao, XL ;

Kreiswirth, BN ;

Drlica, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2581-2584

[12] A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus [J].

Dunne, M ;

Fessel, J ;

Kumar, P ;

Dickenson, G ;

Keiser, P ;

Boulos, M ;

Mogyros, M ;

White, AC ;

Cahn, P ;

O'Connor, M ;

Lewi, D ;

Green, S ;

Tilles, J ;

Hicks, C ;

Bissett, J ;

Schneider, MME ;

Benner, R .

CLINICAL INFECTIOUS DISEASES, 2000, 31 (05) :1245-1252

[13] Management of opportunistic infection prophylaxis in the highly active antiretroviral therapy era [J].

Hansjakob Furrer .

Current Infectious Disease Reports, 2002, 4 (2) :161-174

[14] Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening [J].

Gozalbes, R ;

Brun-Pascaud, M ;

García-Domenech, R ;

Gálvez, J ;

Girard, PM ;

Doucet, JP ;

Derouin, F .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (10) :2764-2770

[15] Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients [J].

Griffith, DE ;

Brown, BA ;

Murphy, DT ;

Girard, WM ;

Couch, L ;

Wallace, RJ .

JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (01) :121-126

[16] Host susceptibility factors in mycobacterial infection - Genetics and body morphotype [J].

Guide, SV ;

Holland, SM .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2002, 16 (01) :163-+

[17]

Heginbothom ML, 2001, INT J TUBERC LUNG D, V5, P539

[18] A retrospective study of the addition of ciprofloxacin to clarithromycin and ethambutol in the treatment of disseminated Mycobacterium avium complex infection [J].

Keiser, P ;

Nassar, N ;

Skiest, D ;

Rademacher, S ;

Smith, JW .

INTERNATIONAL JOURNAL OF STD & AIDS, 1999, 10 (12) :791-794

[19] The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease [J].

Kobashi, Y ;

Matsushima, T .

INTERNAL MEDICINE, 2003, 42 (08) :670-675

[20] Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS [J].

McNabb, J ;

Owens, RC ;

Xuan, DW ;

Quintiliani, R ;

Nightingale, CH ;

Nicolau, DP .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (01) :37-43

← 1 2 3 4 →